Free Webinar On "How US patent reform will affect your filing"

A free webinar on the hottest topic that is patent reform in US is going to be held by Managing IPOn Wednesday November 9, 2011 at 4:00 pm GMT (11:00 am eastern). The title of the webinar is "How US patent reform will affect your filing".

Speakers: 

• Simon Crompton, Managing IP (moderator)
• Paul S. Hunter, Esq., Partner, Foley & Lardner
• Courtenay C. Brinckerhoff, Esq., Partner, Foley & Lardner
• David T. Dutcher, Esq., Head of Prosecution & Asset Management, Invention Law Group

Register for free here. 

DON’T FORGET if you can’t make the live time of this webinar, you can still register, as the footage will be archived and your login details will enable you to listen to it at a time that suits you.

America's new Leahy-Smith America Invents Act

On September 16, 2011, President Mr. Barack Obama has signed into law the Leahy-Smith America Invents Act 2011. This will change US Patent system and main change from “First to Invent” to “First to File”, introduction of Post grant opposition, Pre-issuance submission by third parties (Like third party observation in EP) and many more.

For more details and updated resources, please click here

CPhl India 2011 at Mumbai

One of the biggest pharma events in India that is CPhI India 2011, will be organized in Mumbai at the Bombay Exhibition Centre (BEC) from November 30 to December 2, 2011.  CPhI India 2011 and its co-located events are the most popular and comprehensive pharmaceutical industry events in South Asia.

CPhI India is for pharmaceutical ingredients and intermediates and provides platform for business growth to all the pharmaceutical industry peoples form india as well as international player. It will provide an opportunity to all players to showcase the novel innovative technology and gives access to new opportunity to business.

Patent related to microRNA-122 granted in australia

Australian Patent Office has granted patent in the ‘Sarnow’ patent series for microRNA-122 (miR-122) therapy for treatment of hepatitis C viral (HCV) infections to Regulus Therapeutics Inc which is a biopharmaceutical company leading the discovery and development of innovative drugs targeting microRNAs. This additional patent award will extend the reach of the Sarnow patent estate that already covers the use of an anti-miR inhibitor of miR-122 for the treatment of HCV in the United States and Europe to Australia also. 

BioAsia-12 Conference at Hyderabad In February

BioAsia-11 was a great success with participation of over 2500 delegates from 38 countries from across the globe. As a result of success of that, once again the Government of Andhra Pradesh has again entrusted Pharmexcil and Federation of Asian Biotech Associations (FABA) to organize the ninth edition of BioAsia-12 in Hyderabad, which is scheduled for February 9 to 11 in Hyderabad.

BioAsia is a great occasion  for pharma and biotechnology sector at the international arena.   The theme for BioAsia-12 is “Optimizing Opportunities” . The main focus will be on Vaccines, Contract Research, Exports, Investments and Intellectual Property rights (IPR).

In addition to the buyer seller meet, Pharmexcil is also planning to organize “Pharmexcil- Indian Exporters Pavilion”.

Pharma IPR India Conference 2012 at Mumbai

CPhl is going to organize a three day conference on the most talking topic of the scenario that is patent id pharmaceuticals around the world. The conference is “Pharma IPR India 2012″ and will focus on patent law aspects of india, US and Europe and also cover the patent law of other countries like Japan, Brazil, Thailand and other emerging markets.

Date: 31 January to 2 February 2012
Venue: Mumbai
You can visit the conference website here

Paragraph IV certification update

USFDA has updated Paragraph IV certification list as of September 19, 2011. Table shows the newly added molecule.

DRUG NAME	DOSAGE FORM	STRENGTH	RLD	DATE OF SUBMISSION
Mesalamine	Delayed-release Tablets	800 mg	Asacol HD	7/13/2011
Niacin and Simvastatin	Extended-release Tablets	1000 mg/40 mg	Simcor	2/4/2011